Literature DB >> 26486327

St Gallen molecular subtypes in feline mammary carcinoma and paired metastases-disease progression and clinical implications from a 3-year follow-up study.

M Soares1, J Correia1, M C Peleteiro1, F Ferreira2.   

Abstract

Considering that scarce data are available on disease progression of feline mammary carcinoma (FMC), this study aimed to analyze the clinical, pathological, and immunophenotypic features collected from 61 queens with FMC and to compare the concordance ratios of the expression levels of five molecular markers (ER, PR, fHER2, CK5/6, and Ki-67) between primary tumors (PT) and metastatic lesions. The results showed that cats with luminal A mammary carcinomas (MC) had higher overall survival (924.6 days, p = 0.001) and longer disease-free period (385.4 days, p = 0.005) compared to the ones with other MC subtypes. In fact, queens with triple negative/basal-like MC showed the lowest survival (mean 156.2 days) and the shortest disease-free survival (mean 28 days) among the molecular subtypes of MC. The lung was the organ most frequently affected by metastases, and animals with lung and/or pleural metastases were more likely to display metastases at three or more locations (p = 0.039). A large heterogeneity in protein expression levels was found between PT and paired metastases, with both estrogen and progesterone receptors more likely to be downregulated in metastases. Paired metastases frequently had higher Ki-67 index than PT, whereas fHER2 overexpression was seen in 46 samples (30 %) and CK5/6 expression was found in 50.7 % of metastases (36/71). Results also revealed that disease progression leads to a high percentage of triple negative/basal-like metastases (9/23; 39.1 %) associated with the absence of luminal A subtype in distant metastases (0/23). This study highlights the prognostic importance of immunophenotyping of MC in cats, although the modified protein expression identified in metastases contributes to justify why possible targeted therapies may fail in some animals with metastatic disease. Altogether, the results obtained also demonstrate that FMC can be used as a model to study human breast cancer.

Entities:  

Keywords:  Feline mammary carcinoma; Metastatic disease; Molecular classification; Prognostic biomarkers

Mesh:

Substances:

Year:  2015        PMID: 26486327     DOI: 10.1007/s13277-015-4251-z

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  47 in total

1.  Immunohistochemical analysis of estrogen receptors in feline mammary gland benign and malignant lesions: comparison with biochemical assay.

Authors:  J M de las Mulas; M van Niel; Y Millán; M A Blankenstein; F van Mil; W Misdorp
Journal:  Domest Anim Endocrinol       Date:  2000-01       Impact factor: 2.290

2.  Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.

Authors:  J M Harvey; G M Clark; C K Osborne; D C Allred
Journal:  J Clin Oncol       Date:  1999-05       Impact factor: 44.544

3.  Gene expression profiles of primary breast tumors maintained in distant metastases.

Authors:  Britta Weigelt; Annuska M Glas; Lodewyk F A Wessels; Anke T Witteveen; Johannes L Peterse; Laura J van't Veer
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-09       Impact factor: 11.205

4.  Feline HER2 protein expression levels and gene status in feline mammary carcinoma: optimization of immunohistochemistry (IHC) and in situ hybridization (ISH) techniques.

Authors:  Maria Soares; Jorge Correia; Pedro Rodrigues; Margarida Simões; Alves de Matos; Fernando Ferreira
Journal:  Microsc Microanal       Date:  2013-05-30       Impact factor: 4.127

5.  Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study.

Authors:  Syed K Mohsin; Heidi Weiss; Thomas Havighurst; Gary M Clark; Melora Berardo; Le D Roanh; Ta V To; Zhang Qian; Zho Qian; Richard R Love; D Craig Allred
Journal:  Mod Pathol       Date:  2004-12       Impact factor: 7.842

6.  Tumor-stromal interactions reciprocally modulate gene expression patterns during carcinogenesis and metastasis.

Authors:  Valérie Montel; Evangeline Sari Mose; David Tarin
Journal:  Int J Cancer       Date:  2006-07-15       Impact factor: 7.396

Review 7.  Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research.

Authors:  Ana Bosch; Pilar Eroles; Rosa Zaragoza; Juan R Viña; Ana Lluch
Journal:  Cancer Treat Rev       Date:  2010-01-08       Impact factor: 12.111

8.  Molecular phenotype of primary mammary tumours and distant metastases in female dogs and cats.

Authors:  G Beha; L V Muscatello; B Brunetti; P Asproni; F Millanta; A Poli; C Benazzi; G Sarli
Journal:  J Comp Pathol       Date:  2013-09-21       Impact factor: 1.311

9.  Feline mammary basal-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype.

Authors:  David A Wiese; Tuddow Thaiwong; Vilma Yuzbasiyan-Gurkan; Matti Kiupel
Journal:  BMC Cancer       Date:  2013-09-03       Impact factor: 4.430

10.  Activation of mammalian target of rapamycin (mTOR) in triple negative feline mammary carcinomas.

Authors:  Lorella Maniscalco; Yolanda Millán; Selina Iussich; Mauro Denina; Raquel Sánchez-Céspedes; Francesca Gattino; Bartolomeo Biolatti; Nobuo Sasaki; Takayuki Nakagawa; Maria Flavia Di Renzo; Juana Martín de Las Mulas; Raffaella De Maria
Journal:  BMC Vet Res       Date:  2013-04-15       Impact factor: 2.741

View more
  12 in total

1.  fHER2, PR, ER, Ki-67 and Cytokeratin 5/6 Expression in Benign Feline Mammary Lesions.

Authors:  Maria Soares; Assunção N Correia; Mariana R Batista; Jorge Correia; Fernando Ferreira
Journal:  Animals (Basel)       Date:  2022-06-21       Impact factor: 3.231

2.  Unfavorable Prognostic Effects of the Stem Cell Pluripotency Factor Sox2 in Feline Invasive Mammary Carcinomas.

Authors:  Yohan Truchot; Elie Dagher; Jérôme Abadie; Frédérique Nguyen
Journal:  Front Vet Sci       Date:  2021-01-22

3.  Diagnostic Value of VEGF-A, VEGFR-1 and VEGFR-2 in Feline Mammary Carcinoma.

Authors:  Catarina Nascimento; Andreia Gameiro; João Ferreira; Jorge Correia; Fernando Ferreira
Journal:  Cancers (Basel)       Date:  2021-01-01       Impact factor: 6.639

4.  HER2-positive feline mammary carcinoma.

Authors:  Cláudia Marques; Jorge Correia; Fernando Ferreira
Journal:  Aging (Albany NY)       Date:  2016-08       Impact factor: 5.682

Review 5.  Cat Mammary Tumors: Genetic Models for the Human Counterpart.

Authors:  Filomena Adega; Ana Borges; Raquel Chaves
Journal:  Vet Sci       Date:  2016-08-16

6.  CXCR4 and its ligand CXCL12 display opposite expression profiles in feline mammary metastatic disease, with the exception of HER2-overexpressing tumors.

Authors:  Cláudia S Marques; Ana Rita Santos; Andreia Gameiro; Jorge Correia; Fernando Ferreira
Journal:  BMC Cancer       Date:  2018-07-16       Impact factor: 4.430

7.  Proposal for a Histological Staging System of Mammary Carcinomas in Dogs and Cats. Part 2: Feline Mammary Carcinomas.

Authors:  Florian Chocteau; Marie-Mélanie Boulay; Fanny Besnard; Germain Valeau; Delphine Loussouarn; Frédérique Nguyen
Journal:  Front Vet Sci       Date:  2019-11-07

8.  Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.

Authors:  Elie Dagher; Violette Royer; Paul Buchet; Jérôme Abadie; Delphine Loussouarn; Mario Campone; Frédérique Nguyen
Journal:  BMC Cancer       Date:  2019-12-30       Impact factor: 4.430

9.  Analysis of Copy-Number Variations and Feline Mammary Carcinoma Survival.

Authors:  Hugo Murua Escobar; Ingo Nolte; José Luis Granados-Soler; Kirsten Bornemann-Kolatzki; Julia Beck; Bertram Brenig; Ekkehard Schütz; Daniela Betz; Johannes Junginger; Marion Hewicker-Trautwein
Journal:  Sci Rep       Date:  2020-01-22       Impact factor: 4.379

10.  Evaluation of TFR-1 Expression in Feline Mammary Cancer and In Vitro Antitumor Efficacy Study of Doxorubicin-Loaded H-Ferritin Nanocages.

Authors:  Nicolò Rensi; Alessandro Sammarco; Valentina Moccia; Alessandro Calore; Filippo Torrigiani; Davide Prosperi; Maria Antonietta Rizzuto; Michela Bellini; Raffaella De Maria; Federico Bonsembiante; Silvia Ferro; Rossella Zanetti; Valentina Zappulli; Laura Cavicchioli
Journal:  Cancers (Basel)       Date:  2021-03-12       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.